Raptor Pharmaceutical Receives Notices of Allowance for Key European Patent Applications Protecting Its Cysteamine Portfolio

Raptor Pharmaceutical Corp. RPTP, today announced that the European Patent Office has issued a Notice of Allowance for a key patent covering the use of enteric-coated, delayed-release oral formulations of cysteamine bitartrate, including Raptor's proprietary microbead formulation, RP103 Raptor holds exclusive, worldwide licenses to this and other related patent applications, which are owned by the Regents of the University of California, and are based on work performed at the University of California, San Diego ("UCSD"). In 2011, counterpart patents were granted in the US directed to DR cysteamine compositions, including RP103, and methods of use for any indication, including nephropathic cystinosis. "Having submitted a Marketing Authorization Application for RP103 for the potential treatment of nephropathic cystinosis to the European Medicines Agency, this notice of allowance gives the Company key additional IP protection in Europe," commented Ted Daley, President of Raptor.